Transcenta Holding Limited Stock price

Equities

6628

KYG9005B1041

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
2.08 HKD -0.95% Intraday chart for Transcenta Holding Limited +0.97% -42.06%

Financials

Sales 2023 53.85M 7.45M 58.32M Sales 2024 * 195M 27.04M 212M Capitalization 802M 111M 869M
Net income 2023 -463M -64.08M -501M Net income 2024 * -468M -64.77M -507M EV / Sales 2023 25.2 x
Net Debt 2023 * 230M 31.84M 249M Net cash position 2024 * 438M 60.62M 474M EV / Sales 2024 * 1.87 x
P/E ratio 2023
-2.86 x
P/E ratio 2024 *
-1.75 x
Employees 318
Yield 2023 *
-
Yield 2024 *
-
Free-Float 89.53%
More Fundamentals * Assessed data
Dynamic Chart
Transcenta Holding Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcenta Publishes Promising Results of Anti-Tumor Drug's Efficacy and Safety in European Journal MT
Transcenta Holding Limited Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging CI
Transcenta Presents Data on Gastric/Gastroesophageal Cancer Treatment Trial at Spain Oncology Meet MT
Transcenta Holding Limited Presents Updated Efficacy Data from the Expansion Cohort of the Transtar102 of Osemitamab Plus Capox Chemotherapy Study as the First-Line Treatment of Advanced G/Gej Cancer At the ESMO Congress 2023 in Madrid, Spain CI
US FDA Approves Phase 3 Trial for Transcenta's Gastric Cancer Treatment MT
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients CI
Transcenta Widens Loss in H1 MT
Transcenta Holding Limited Announces Management Changes, Effective August 23, 2023 CI
Transcenta Holding Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Transcenta Moves to Phase II Trial of Osteoporosis Drug MT
Transcenta Holding Limited Receives Approval from China Center for Drug Evaluation to Initiate Phase II Clinical Trial of TST002(Blosozumab) CI
China, South Korea Approve Transcenta's Phase 3 Trial for Anti-Tumor Medication MT
Transcenta Holding Limited Receives Approval from China CDE and South Korea MFDS to Initiate Transtar301 Global Phase III Pivotal Trial of Osemitamab CI
Transcenta Holding Limited Presents Pfs Data by Cldn18.2 Expression Level from Phase I/Ii Study of Osemitamab Plus Capecitabine and Oxaliplatin as the First-Line Treatment of Advanced G/Gej Cancer CI
More news
1 day-0.95%
1 week+0.97%
Current month-11.11%
1 month-11.11%
3 months-27.27%
6 months-48.51%
Current year-42.06%
More quotes
1 week
1.91
Extreme 1.91
2.17
1 month
1.84
Extreme 1.84
2.49
Current year
1.84
Extreme 1.84
4.00
1 year
1.84
Extreme 1.84
6.20
3 years
1.84
Extreme 1.84
16.18
5 years
1.84
Extreme 1.84
16.18
10 years
1.84
Extreme 1.84
16.18
More quotes
Managers TitleAgeSince
Founder 57 10-07-31
Director of Finance/CFO 47 21-12-16
Chief Tech/Sci/R&D Officer 52 22-08-07
Members of the board TitleAgeSince
Founder 53 18-11-30
Founder 57 10-07-31
Director/Board Member 50 21-09-13
More insiders
Date Price Change Volume
24-03-28 2.08 -0.95% 24,500
24-03-27 2.1 -1.41% 0
24-03-26 2.13 -0.47% 30,000
24-03-25 2.14 -1.38% 25,500
24-03-22 2.17 +6.37% 75,500

Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT

More quotes
Transcenta Holding Limited is a China-based investment holding company engaged in the discovery, research, development, manufacturing and business development of biopharmaceuticals in the clinical stage. The Company's products include MSB2311, TST001, TST005, TST002, TST004, TST003, TST008, MSB0254 and TST006. The Company's all products are in the research and development (R&D) stage and have not been commercialized. The Company also provides contract developmentand manufacturing organization (CDMO) services, mainly including process development services, GMP / cGMP production services, cell line development services, sample testing services, formula optimization services and drug formation research.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.921 CNY
Average target price
7.792 CNY
Spread / Average Target
+305.70%
Consensus
  1. Stock
  2. Equities
  3. Stock Transcenta Holding Limited - Hong Kong S.E.